Elastase-2-A (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Elastase-2-A (CELA2A; UniProt P08217) produced in HEK293 cells. Serine protease suited for substrate cleavage assays, inhibitor profiling, and antibody validation workflows.
Expression system
HEK293
Cat. #
REC-Elastase2A

In stock

SKU
REC-Elastase2A
$498.00

Target Overview

Elastase-2-A (CELA2A; UniProt P08217) is a secreted serine protease of the chymotrypsin-like elastase family, encoded by the CELA2A gene. The full-length human protein spans 269 amino acids and circulates in plasma, where it has been characterised as a regulator of insulin signalling and platelet activation. This recombinant form is produced in HEK293 mammalian cells, a system that supports the folding, disulfide-bond formation, and glycosylation patterns expected for a secreted serine protease, making it suitable for functional enzymatic studies where post-translational modifications may influence activity or inhibitor binding. Researchers use this reagent primarily in three contexts. First, in enzymatic activity assays: Elastase-2-A cleaves elastin-like peptide substrates and synthetic chromogenic or fluorogenic substrates (e.g., succinyl-Ala-Ala-Ala-p-nitroanilide), enabling Michaelis-Menten kinetic characterisation and kcat/Km determination. Second, in inhibitor screening: the recombinant enzyme provides a defined, reproducible source of active protease for IC50 measurements against candidate small-molecule or peptide inhibitors. Third, in antibody validation: as a well-characterised recombinant standard, it serves as a positive-control antigen in Western blot loading and immunoprecipitation pull-down experiments. Researchers requiring a matched immunodetection reagent can pair this recombinant with the Triple Point Biologics Elastase-2-A antibody (SKU: RP-Elastase2A), validated for Western blot against human tissue. The recombinant and antibody together support orthogonal confirmation of endogenous CELA2A expression in pancreatic and intestinal tissue lysates.

Background

Elastase-2-A (CELA2A; EC 3.4.21.71) is a chymotrypsin-like serine endopeptidase that is synthesised in the exocrine pancreas and secreted into the circulation. Beyond its classical role in luminal digestion of dietary proteins, published studies have identified CELA2A as an extrapancreatic signalling protease with measurable effects on glucose homeostasis. Specifically, circulating Elastase-2-A has been reported to enhance insulin receptor signalling, stimulate insulin secretion, promote insulin degradation, and reduce platelet hyperactivation — observations that have positioned CELA2A as a research target in metabolic physiology. CELA2A has also appeared as a candidate locus in several human genetics studies. A proteome-wide association and GWAS integration study by Zhao Y et al. (2025, Mol Neurobiol; PMID 40266545) identified CELA2A among proteins with genetically predicted expression changes associated with dementia risk, suggesting the protease may be of interest to researchers studying neurological phenotypes alongside its metabolic roles. Separately, gut-focused proteomic and transcriptomic analyses have detected CELA2A-related signatures in intestinal inflammation models; Cao T et al. (2025, J Immunol Res; PMID 41079267) identified modulation of the pancreatic secretion pathway — in which CELA2A participates — in a murine DSS-induced colitis model treated with leonurine. These findings have motivated use of recombinant CELA2A in ex-vivo intestinal assay systems. Additional published work has placed CELA2A within larger genetic co-expression and polygenic analyses of hypertension (Mani A, Cell Mol Life Sci, 2024; PMID 38691164) and substance use susceptibility (Veerappa A, Front Neurosci, 2024; PMID 38660223), further illustrating how the protease's chromosomal locus has been captured in population-scale variant studies. A fecal metaproteomic survey of adolescents with bipolar depression also detected gut-derived elastase-family proteins as differentially abundant (Zhao Z et al., Transl Psychiatry, 2026; PMID 41690939), consistent with growing interest in pancreatic enzyme signatures in microbiome research. Collectively, these publications reflect a research landscape in which CELA2A is studied across metabolic, neurological, and gastrointestinal contexts. Recombinant Elastase-2-A provides the defined, activity-characterised protein standard needed to support enzyme kinetics, substrate mapping, inhibitor profiling, and antigen validation experiments that underpin this body of work. Triple Point Biologics has produced proteinase-related research reagents since 1994; this recombinant is prepared under conditions that preserve catalytic competence appropriate for in-vitro biochemical studies.

Applications

  • Substrate cleavage activity assay using succinyl-Ala-Ala-Ala-p-nitroanilide or fluorogenic elastin-mimetic peptides for Michaelis-Menten kinetic characterisation
  • Small-molecule inhibitor IC50 determination in serine protease inhibitor screens
  • Positive-control antigen for Western blot validation of anti-CELA2A antibodies (pairs with Triple Point Biologics SKU: RP-Elastase2A)
  • Immunoprecipitation pull-down standard to confirm antibody specificity against endogenous CELA2A in pancreatic lysates
  • Substrate specificity profiling by mass spectrometry using proteomic peptide libraries
  • Enzymatic standard for spike-in calibration in fecal or plasma metaproteomic workflows measuring elastase activity
  • Binding affinity determination (Kd, kon, koff) by surface plasmon resonance or biolayer interferometry with candidate inhibitor compounds

References

  1. Zhao Z et al. Fecal metaproteomics reveals alterations in gut microbiota and intestinal proteins in adolescents with bipolar depression. Transl Psychiatry. 2026. doi:10.1038/s41398-026-03899-6. PMID: 41690939.
  2. Cao T et al. Leonurine Alleviates DSS-Induced Colitis in Mice by Regulating Pancreatic Secretion Pathway and Gut Microbiota. J Immunol Res. 2025. doi:10.1155/jimr/6626309. PMID: 41079267.
  3. Zhao Y et al. Combining GWAS Summary Data and Proteomics Identified Potential Drug Targets in Dementia. Mol Neurobiol. 2025. doi:10.1007/s12035-025-04967-6. PMID: 40266545.
  4. Mani A. Update in genetic and epigenetic causes of hypertension. Cell Mol Life Sci. 2024. doi:10.1007/s00018-024-05220-4. PMID: 38691164.
  5. Veerappa A. Coordination among frequent genetic variants imparts substance use susceptibility and pathogenesis. Front Neurosci. 2024. doi:10.3389/fnins.2024.1332419. PMID: 38660223.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Azurophilic granules; neutrophils; secreted on activation

Frequently Asked Questions

What is the expected molecular weight of recombinant Elastase-2-A on SDS-PAGE and Western blot?

The full-length human CELA2A protein is 269 amino acids, giving a theoretical MW of ~29 kDa. However, because this recombinant is produced in HEK293 cells, N-linked glycosylation adds approximately 3–6 kDa, so expect a diffuse band running at 32–35 kDa under reducing SDS-PAGE conditions. Non-reducing conditions may shift migration slightly due to intact disulfide bonds. Our matched antibody (RP-Elastase2A) is validated against this glycosylated form, so the band you observe with the recombinant as a positive control should align with endogenous CELA2A in plasma or pancreatic lysates.

Is this recombinant Elastase-2-A the mature processed form or does it include the signal peptide?

The recombinant is expressed as the mature secreted form. The 29-amino-acid signal peptide (residues 1–29) is cleaved co-translationally during secretion from HEK293 cells, so the product begins at the predicted N-terminus of the processed enzyme (Ala-30). The zymogen propeptide is also removed, yielding the catalytically competent serine protease domain. If your experiment requires comparison to a specific isoform or propeptide-containing precursor, confirm the construct boundaries in the Certificate of Analysis before use.

What substrates does recombinant Elastase-2-A cleave and how do I set up a chromogenic activity assay?

CELA2A cleaves the canonical elastase substrate succinyl-Ala-Ala-Ala-p-nitroanilide (Suc-AAA-pNA), with absorbance monitored at 405 nm. A practical starting point: 50–200 nM recombinant Elastase-2-A, substrate concentrations spanning 0.1–5 mM to bracket Km, in 50 mM Tris-HCl pH 7.5, 150 mM NaCl at 37°C. For fluorogenic assays, MeO-Suc-Ala-Ala-Pro-Val-AMC (excitation 380 nm / emission 460 nm) offers greater sensitivity. Run a no-enzyme blank and confirm linearity over at least 10 minutes before extracting initial velocity values for Michaelis-Menten fitting.

What buffer conditions are optimal for Elastase-2-A activity assays and does glycerol in the storage buffer interfere?

Activity is well supported in 50 mM Tris-HCl pH 7.5, 150 mM NaCl — the same buffer used for storage — so minimal buffer exchange is needed. The 10% glycerol in the storage buffer is generally tolerated at final assay concentrations below 1%, achievable by diluting the enzyme at least 1:10 into assay buffer before adding substrate. Avoid EDTA-containing buffers; while CELA2A is a serine protease not requiring divalent cations for catalysis, EDTA can chelate trace metals that stabilise the fold. pH optimum is 7.5–8.0; activity drops noticeably below pH 6.5.

What starting concentration of recombinant Elastase-2-A should I use for inhibitor IC50 screening?

For inhibitor screening, use the minimum enzyme concentration that gives a robust, linear signal — typically 50–100 nM recombinant Elastase-2-A with Suc-AAA-pNA at or below Km (≈0.5 mM is a reasonable estimate for CELA2A). Running enzyme well below substrate Km keeps the competitive inhibition model accurate and avoids substrate depletion artefacts. Pre-incubate enzyme with inhibitor for 15–30 minutes at room temperature before adding substrate to capture slow-binding inhibitors. Always confirm enzyme stability over the incubation period with a no-inhibitor time-course control.

Can I use recombinant Elastase-2-A as a positive control for Western blot with the matched RP-Elastase2A antibody?

Yes — this is one of the primary intended uses. REC-Elastase2A and RP-Elastase2A are produced and validated together in our laboratory, so compatibility is confirmed rather than assumed. Load 20–50 ng of recombinant per lane under reducing conditions; the antibody should detect a clean 32–35 kDa band at typical working dilutions of 1:500–1:2,000 (see the RP-Elastase2A datasheet for the validated dilution range). This positive control is particularly useful when running plasma samples or pancreatic tissue lysates where endogenous CELA2A signal intensity is uncertain.

How much recombinant Elastase-2-A should I load for a Western blot positive control lane?

20–50 ng per lane is the recommended starting point when using RP-Elastase2A at 1:1,000 dilution on standard PVDF or nitrocellulose membranes. If you are optimising a new membrane or detection system, run a titration at 10, 25, and 50 ng to identify the linear detection range before committing to a fixed loading amount. Because the HEK293-expressed protein is glycosylated, it migrates as a slightly diffuse band; overloading (>100 ng) tends to smear rather than sharpen the signal. Pair with a plasma sample of known CELA2A expression to calibrate relative band intensities.

How should I store and handle recombinant Elastase-2-A to preserve enzymatic activity over time?

Store at −20°C in single-use aliquots immediately upon receipt. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is formulated to maintain activity through a single freeze-thaw cycle; repeated freeze-thaw leads to measurable activity loss in serine proteases. Prepare working dilutions fresh in assay buffer on ice and use within 4 hours. If you need to hold diluted enzyme on the bench, add 0.1% BSA (protease-free) as a carrier to reduce adsorptive loss at low concentrations. Do not add reducing agents such as DTT or BME unless your protocol specifically requires them, as these can disrupt the disulfide bonds critical to CELA2A fold integrity.

Validation imagery coming soon

Western blot validation figures for REC-Elastase2A will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →